Fig. 2From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expressionBMD Loss was repressed by ZOL treatment in HIV patients receiving tenofovir treatment. a Model-based mean longitudinal changes in BMD at the lumbar spine in 48Â weeks in ZOL-treated HIV patients receiving tenofovir treatment. b Model-based mean BMD percentage change at the lumbar spine from baseline in 48Â weeks in ZOL-treated HIV patients receiving tenofovir treatment. c Model-based mean longitudinal changes in lumbar spine t scores in 48Â weeks in ZOL-treated HIV patients receiving tenofovir treatment. d Model-based mean longitudinal changes in lumbar spine z scores in 48Â weeks in ZOL-treated HIV patients receiving tenofovir treatmentBack to article page